Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of remimazolam toluene sulfonate on cerebral blood flow perfusion
ChiCTR2100046501Phase 4Recruiting
- Sponsor
- Hengshui People's Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam in cerebral hypoperfusion (CCH) and procedural sedation and analgesia (PSA) (2 arms), sponsored by Hengshui People's Hospital. Primary endpoints: Carotid artery systolic and diastolic flow velocity, Carotid resistance index and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
remimazolam
03
Conditions
cerebral hypoperfusion (CCH)procedural sedation and analgesia (PSA)
Beyond the preview
Go deeper on ChiCTR2100046501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046501.